Acute Disseminated Intravascular Coagulation After Prophylactic Nailing of the Femur in a Patient with Metastatic Prostate Cancer

2020 ◽  
Vol 10 (1) ◽  
pp. e0370-e0370
Author(s):  
Daniel Z. You ◽  
Joseph K. Kendal ◽  
Paul Duffy ◽  
Michael J. Monument ◽  
Prism S. Schneider
Keyword(s):  
Prostate Cancer ◽  
Disseminated Intravascular Coagulation ◽  
Metastatic Prostate Cancer ◽  
Intravascular Coagulation

scholarly journals Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Kavita Agrawal ◽  
Nirav Agrawal ◽  
Levin Miles
Keyword(s):  
Prostate Cancer ◽  
Weight Loss ◽  
Disseminated Intravascular Coagulation ◽  
Metastatic Prostate Cancer ◽  
Degradation Products ◽  
Specific Antigen ◽  
Mass Effect ◽  
Whole Body ◽  
Initial Manifestation ◽  
Intravascular Coagulation

A 70-year-old male presented with hematuria and bruising of arms and legs for the last three days. He also complained of urinary frequency and hesitancy and weight loss of 40 pounds over a span of four months. Initial blood tests showed prothrombin time (PT) of 25.1 seconds, international normalized ratio (INR) of 2.5, partial thromboplastin time (PTT) of 43.9 seconds, fibrinogen of 60 mg/dl, fibrin degradation products (FDP) of more than 20 μg/ml, and platelets of 88,000/μl. The impression was disseminated intravascular coagulation (DIC). A search was initiated to determine the underlying etiology precipitating DIC. Due to urinary symptoms and weight loss, prostate-specific antigen (PSA) was ordered. PSA was elevated at 942 μg/dl. Computed tomography (CT) of the abdomen and pelvis without contrast showed an enlarged prostate with mass effect on the bladder base, left-sided hydronephrosis, and numerous enlarged pelvic lymph nodes. A bone scan of the whole body showed increased sclerosis of the L3 vertebral body. There was a concern for metastatic prostate cancer precipitating DIC. On first admission, our patient’s DIC was stabilized with FFP and cryoprecipitate transfusions. He refused chemotherapy, and degarelix was not economically feasible. Accordingly, he was started on androgen deprivation therapy (ADT), bicalutamide, and leuprolide as an inpatient, pending the tissue biopsy. The patient refused a prostate biopsy. A bone marrow biopsy was performed which confirmed metastatic prostate adenocarcinoma. The patient was stable for discharge with a plan for outpatient chemotherapy. Subsequently, he was lost to follow-up with the oncology. Six months after the initial presentation, he was readmitted with hematuria. Repeat PSA worsened to 1,970 μg/dl. Blood work was consistent with acute DIC. He refused chemotherapy again. So, he was restarted on ADT. However, his hematuria and DIC panel were worsening. He was emergently started on docetaxel as an inpatient (after patient agreement). Within three days of starting chemotherapy, his hematuria resolved and DIC panel showed consistent improvement.

Sign in / Sign up

Export Citation Format

Share Document